Xifaxan® (rifaximin) 550 mg Tablets Now Available in U.S. Pharmacies
RALEIGH, N.C.—-Salix Pharmaceuticals, Ltd. today announced the availability of Xifaxan® 550 mg tablets for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older.



